Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
These 3 Dividend Stocks Have Raised Their Payouts for a Combined 187 Years. Here's Why That Matters To Passive Income Lovers
Earned income disappears the moment you stop working. Dividend income keeps arriving every quarter.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
3 Unstoppable Growth Stocks For Years Of Passive Income
Passive income separates a paycheck from a portfolio. Earned income stops when you stop working, but dividends landing quarterly do not.
J&J Sees Continued MedTech Improvement in Q1, Eyes Better 2026
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
Birch Hill Investment Advisors LLC Decreases Holdings in Johnson & Johnson $JNJ
Birch Hill Investment Advisors LLC trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 134,441 shares of the company's stock after selling 4,014 shares during the period.
First Horizon Corp Decreases Position in Johnson & Johnson $JNJ
First Horizon Corp lessened its stake in Johnson and Johnson (NYSE: JNJ) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 141,272 shares of the company's stock after selling 2,498 shares during the quarter. Johnson and Johnson makes up approximately 1.3%
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?
JNJ's Innovative Medicine unit posts strong Q1 growth despite Stelara hit, with key drugs and new launches positioning the segment for long-term growth.
